Stocks · News reference
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 50 percent increase over losses of $(0.60) per share from
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lexeo Therapeutics, a clinical-stage biotech company, announced it will participate in a fireside chat at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The company is focused on developing genetic disease treatments, including LX2006 for Friedreich ataxia and LX2020 for arrhythmogenic cardiomyopathy.
Lexeo Therapeutics announced that its abstract for LX2006, an AAV-based gene therapy for Friedreich ataxia, has been accepted for oral presentation at the MDS 2026 Congress in Seoul. The presentation will highlight early stabilization or improvement in mFARS scores in LX2006-treated participants compared to propensity-matched controls, along with new subscore analyses. LX2006 has received multiple FDA designations including Breakthrough Therapy and Orphan Drug status.
Filed: 2026-09-29 AccNo: 0001193125-26-407555 Size: 184 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.